Neogenomics (NEO) Akcija Цена
Neogenomics Цена
U poslednjih 19 godina prihod Neogenomics rastao je 28,2 % godišnje i dostigao 727,33 М USD. Zarada po akciji rasla je 50,4 % godišnje u poslednjih 8 godina. Za Neogenomics neto marža od -14,9 % je pala u odnosu na -1,7 % pre nekoliko godina. Konsenzusna 12-mesečna ciljana cena za Neogenomics je 19,00 USD, oko iznad kurs za 15,2 %. Od 16 analitičara 11 preporučuje kupovinu — ukupni konsenzus je Kupi.
Cena akcije Neogenomics
Pristupite ovim podacima preko Eulerpool API-ja
100.000 zahteva/mes. besplatno · bez kartice
Neogenomics poslovni model i analiza akcije
Često postavljana pitanja o akciji Neogenomics
Neogenomics Inc. (NYSE: NEO) is a leading provider of cancer-focused genetic testing services. The company's business model revolves around offering comprehensive testing solutions that aid in the diagnosis and treatment of cancer patients. Neogenomics Inc. operates through a network of laboratories and provides advanced molecular and cytogenetic testing, helping healthcare professionals make informed decisions based on genetic information. With a focus on precision medicine, Neogenomics Inc. delivers personalized treatment options, improving patient outcomes and delivering high-quality diagnostic services.
Neogenomics Inc is primarily active in the healthcare and diagnostic laboratory services industries.
The main competitors of Neogenomics Inc in the market are Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, and NeoGenomics Laboratories.
Neogenomics Inc is a leading provider of cancer-focused genetic testing services. Founded in 2001, the company is headquartered in Fort Myers, Florida. With an extensive network of laboratories across the United States, Neogenomics offers cutting-edge diagnostic and pharmaceutical services to aid in the personalized treatment and monitoring of various types of cancers. Over the years, Neogenomics has grown its portfolio of tests and services, catering to the evolving needs of healthcare professionals and patients. Their dedication to innovation and quality has positioned them as a trusted partner in the fight against cancer.
Some significant milestones achieved by Neogenomics Inc include its acquisition of Clarient Inc in 2015, which expanded its personalized medicine capabilities. The company also received full approval from the New York State Department of Health in 2017, allowing it to offer its services in all 50 states. Neogenomics Inc has strengthened its position in the molecular testing market through strategic collaborations with pharmaceutical companies. Furthermore, in 2019, the company completed its acquisition of Genoptix, enhancing its oncology diagnostics capabilities. These milestones demonstrate Neogenomics Inc's commitment to growth and innovation in the field of cancer diagnostics and personalized medicine.
Neogenomics Inc is primarily present in the United States.
Neogenomics Inc prides itself on its commitment to excellence and innovation in the field of precision medicine. With a strong corporate philosophy centered around patient care and advancing the fight against cancer, Neogenomics Inc places great importance on ethical practices and providing accurate diagnostic solutions. The company believes in fostering a collaborative environment to bring cutting-edge technologies and personalized medicine to patients globally. By constantly pushing boundaries and embracing transformative ideas, Neogenomics Inc aims to revolutionize how cancer is detected and treated. Through its dedication to quality, integrity, and patient-centric values, the company sets itself apart as a leader in the field.
Analitičari trenutno postavljaju prosečnu ciljanu cenu 19,00 USD za akciju Neogenomics (medijana: 19,00 USD), što znači +15,2 % u odnosu na poslednju cenu. Konsenzus se zasniva na 16 ocena.
16 analitičara trenutno ocenjuje akciju Neogenomics: 11 preporučuje kupovinu, 5 držanje i 0 prodaju. Za 2026 analitičari očekuju da Neogenomics ostvari prihod 805,18 М USD i zaradu po akciji 0,92 USD.
Po trenutnom kursu akcija Neogenomics kotira 14,73 EUR (16,50 USD).
Akcija Neogenomics (NEO) kotira na 5 berze, uključujući: NASDAQ (NEO), SIX (Zürich) (NG9.SW), Frankfurt (NG9.F), München (NG9.MU), Düsseldorf (NG9.DU).
Neogenomics Inc is a leading company in oncology diagnostics and offers a wide range of solutions and products to its customers. The company has been listed on the stock exchange since 2001 and is the largest provider of cancer diagnostics services in the United States. Translate the text to the best possible English.
očekivana prihod od Neogenomics je 805,18 М USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.
očekivana dobit od Neogenomics je 23,72 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.
Odnos cene i zarade (KGV) za Neogenomics je trenutno 17,90. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Neogenomics.
Odnos cene i prihoda (KUV) za Neogenomics je trenutno 0,53. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Neogenomics.
Eulpool score kvaliteta za Neogenomics je 3/10.
ISIN za Neogenomics je US64049M2098. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.
WKN za Neogenomics je 120159. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.
Ticker za Neogenomics je NEO. Simbol tikera se koristi za trgovinu akcijama Neogenomics na berzanskom tržištu.
Neogenomics акција
Neogenomics Peer grupa
Neogenomics Тикер
Neogenomics FIGI
Sve ključne metrke i detaljne analize Neogenomics u dubinskoj analizi
Naša analiza akcija za akciju Neogenomics uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Neogenomics. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: